|
1
|
Jimenez P, Pathak A and Phan AT: The role
of taxanes in the management of gastroesophageal cancer. J
Gastrointest Oncol. 2:240–249. 2011.PubMed/NCBI
|
|
2
|
Ajani JA, Barthel JS, Bekaii-Saab T, et
al: Esophageal cancer. J Natl Compr Canc Netw. 6:818–849. 2008.
|
|
3
|
Wolf MC, Stahl M, Krause BJ, et al:
Curative treatment of oesophageal carcinoma: current options and
future developments. Radiat Oncol. 6:552011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wright JC: Update in cancer chemotherapy:
gastrointestinal cancer, cancer of the small intestines,
gallbladder, liver, and esophagus. J Natl Med Assoc. 78:753–766.
1986.
|
|
6
|
Kim SJ, Chung MJ, Kim JS, et al:
Deciphering the role of paclitaxel in the SKGT4 human esophageal
adenocarcinoma cell line. Int J Oncol. 39:1587–1591.
2011.PubMed/NCBI
|
|
7
|
Legha SS, Ring S, Papadopoulos N, Raber M
and Benjamin RS: A phase II trial of taxol in metastatic melanoma.
Cancer. 65:2478–2481. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Holmes FA, Walters RS, Theriault RL, et
al: Phase II trial of taxol, an active drug in the treatment of
metastatic breast cancer. J Natl Cancer Inst. 83:1797–1805. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Einzig AI, Wiernik PH, Sasloff J, Runowicz
CD and Goldberg GL: Phase II study and long-term follow-up of
patients treated with taxol for advanced ovarian adenocarcinoma. J
Clin Oncol. 10:1748–1753. 1992.PubMed/NCBI
|
|
10
|
van Steenbergen LN, Elferink MA, Krijnen
P, et al: Improved survival of colon cancer due to improved
treatment and detection: a nationwide population-based study in The
Netherlands 1989–2006. Annal Oncol. 21:2206–2212. 2010.PubMed/NCBI
|
|
11
|
Ajani J: Therapy of localized esophageal
cancer: it is time to reengineer our investigative strategies.
Onkologie. 31:360–361. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Faried A, Faried LS, Kimura H, et al:
Differential sensitivity of paclitaxel-induced apoptosis in human
esophageal squamous cell carcinoma cell lines. Cancer Chemother
Pharmacol. 57:301–308. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tacar O, Sriamornsak P and Dass CR:
Doxorubicin: an update on anticancer molecular action, toxicity and
novel drug delivery systems. J Pharm Pharmacol. 65:157–170. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Buchholz TA, Stivers DN, Stec J, et al:
Global gene expression changes during neoadjuvant chemotherapy for
human breast cancer. Cancer J. 8:461–468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Enzinger PC and Mayer RJ: Esophageal
cancer. New Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rowinsky EK and Donehower RC: The clinical
pharmacology of paclitaxel (Taxol). Semin Oncol. 20:16–25.
1993.PubMed/NCBI
|
|
17
|
Park KW, Kang SH, Park KH, et al:
Sirolimus- vs. paclitaxel-eluting stents for the treatment of
unprotected left main coronary artery stenosis: complete 2-year
follow-up of a two-center registry. Int J Cardiol. 151:89–95.
2011.PubMed/NCBI
|
|
18
|
Toiyama Y, Tanaka K, Konishi N, et al:
Administration sequence-dependent antitumor effects of paclitaxel
and 5-fluorouracil in the human gastric cancer cell line MKN45.
Cancer Chemother Pharmacol. 57:368–375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zimmermann M, Arachchige-Don AS, Donaldson
MS, Dallapiazza RF, Cowan CE and Horne MC: Elevated cyclin G2
expression intersects with DNA damage checkpoint signaling and is
required for a potent G2/M checkpoint arrest response to
doxorubicin. J Biol Chem. 287:22838–22853. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim AH, Khursigara G, Sun X, Franke TF and
Chao MV: Akt phosphorylates and negatively regulates apoptosis
signal-regulating kinase 1. Mol Cell Biol. 21:893–901. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang HB, Lu P, Guo QY, Zhang ZH and Meng
XY: Baicalein induces apoptosis in esophageal squamous cell
carcinoma cells through modulation of the PI3K/Akt pathway. Oncol
Lett. 5:722–728. 2013.PubMed/NCBI
|
|
22
|
Lin ML, Lu YC, Chen HY, Lee CC, Chung JG
and Chen SS: Suppressing the formation of lipid raft-associated
Rac1/PI3K/Akt signaling complexes by curcumin inhibits
SDF-1alpha-induced invasion of human esophageal carcinoma cells.
Mol Carcinog. Nov 28–2012.(Epub ahead of print). View Article : Google Scholar
|
|
23
|
Gen Y, Yasui K, Nishikawa T and Yoshikawa
T: SOX2 promotes tumor growth of esophageal squamous cell carcinoma
through the AKT/mammalian target of rapamycin complex 1 signaling
pathway. Cancer Sci. 104:810–816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shigaki H, Baba Y, Watanabe M, et al:
PIK3CA mutation is associated with a favorable prognosis among
patients with curatively resected esophageal squamous cell
carcinoma. Clin Cancer Res. 19:2451–2459. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ou Y, Ma L, Ma L, et al: Overexpression of
cyclin B1 antagonizes chemotherapeutic-induced apoptosis through
PTEN/Akt pathway in human esophageal squamous cell carcinoma cells.
Cancer Biol Ther. 14:45–55. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nguyen DM, Chen GA, Reddy R, et al:
Potentiation of paclitaxel cytotoxicity in lung and esophageal
cancer cells by pharmacologic inhibition of the phosphoinositide
3-kinase/protein kinase B (Akt)-mediated signaling pathway. J
Thorac Cardiovasc Surg. 127:365–375. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Y, Sun Y, Chen L, et al: miRNA-200c
increases the sensitivity of breast cancer cells to doxorubicin
through the suppression of E-cadherin-mediated PTEN/Akt signaling.
Mol Med Rep. 7:1579–1584. 2013.PubMed/NCBI
|
|
28
|
Yu YH, Kuo HP, Hsieh HH, et al:
Ganoderma tsugae induces S phase arrest and apoptosis in
doxorubicin-resistant lung adenocarcinoma H23/0.3 cells via
modulation of the PI3K/Akt signaling pathway. Evid Based Complement
Alternat Med. 2012:3712862012.PubMed/NCBI
|
